Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.53 |
| ▸ | MMP13 | P45452 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | STS | P08842 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8108181 | 1.00 | GPR119 (0.53) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL23329483 | 0.93 | KAT7 (0.51) | GPR119MMP13KMT2AMEN1 | |
| SCHEMBL10265584 | 0.93 | GPR119 (0.57) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL31540197 | 0.90 | KMT2A (0.51) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL23330155 | 0.89 | GPR119 (0.52) | GPR119MMP13STSKDM4EPKM | |
| SCHEMBL13832841 | 0.86 | GPR119 (0.51) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL13832628 | 0.86 | GPR119 (0.51) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL1502200 | 0.86 | GPR119 (0.51) | GPR119MMP13KMT2AMEN1STS | |
| SCHEMBL25274092 | 0.86 | GPR119 (0.57) | GPR119MMP13KMT2AMEN1 | |
| SCHEMBL28978030 | 0.86 | GPR119 (0.58) | GPR119MMP13KMT2AMEN1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017127371-A1 | BRUTON'S TYROSINE KINASE INHIBITORS | SUNNYLIFE PHARMA INC. (US) | 2017-07-27 | — | — | WO | disclosed |
| US-8252824-B2 | Substituted N-phenyl-bipyrrolidine carboxamides and therapeutic use thereof | SANOFI (FR) | 2012-08-28 | — | — | US | disclosed |
| US-20120065234-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065234-A1 | SUBSTITUTED N-PHENYL-BIPYRROLIDINE CARBOXAMIDES AND THERAPEUTIC USE THEREOF | HRH3, HRH4, CNR1 | GPR119 21/4885MMP13 4610/4885KMT2A 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.